IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>On 22 July, <a href="https://www.smartkarma.com/entities/arvida-group-ltd" target="_blank" data-smartkarma-citation="entities:14485:1" rel="noopener">Arvida (ARV NZ)</a> entered a scheme implementation agreement with Stonepeak at NZ$1.70, a 65.0% premium to the undisturbed price.</li>
<li>The transaction will require OIO approval, statutory supervisors' consent and shareholder approval. The <a href="https://www.smartkarma.com/entities/metlifecare-ltd" target="_blank" data-smartkarma-citation="entities:19219:1" rel="noopener">Metlifecare Ltd (MET NZ)</a> precedent suggests that the OIO and statutory supervisor should be forthcoming.</li>
<li>The offer is attractive, and shareholders representing 18% of outstanding shares are supportive. At the last close and for a November payment, the gross/annualised spread was 4.9%/14.2%.  </li>
</ul>


On 22 July, Arvida (ARV NZ) entered a scheme implementation agreement with Stonepeak at NZ$1.70, a 65.0% premium to the undisturbed price.
The transaction will require OIO approval, statutory supervisors' consent and shareholder approval. The Metlifecare Ltd (MET NZ) precedent suggests that the OIO and statutory supervisor should be forthcoming.
The offer is attractive, and shareholders representing 18% of outstanding shares are supportive. At the last close and for a November payment, the gross/annualised spread was 4.9%/14.2%.  


Arvida Group (ARV NZ): Stonepeak’s Binding Proposal at NZ$1.70

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

<ul>
<li>Hospital operator <a href="https://www.smartkarma.com/entities/ramsay-health-care-ltd" target="_blank" data-smartkarma-citation="entities:673:1" rel="noopener">Ramsay Health Care (RHC AU)</a> has <a href="https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02511581-2A1369312?access_token=83ff96335c2d45a094df02a206a39ff4" target="_blank" rel="noopener">announced</a> an unsolicited, non-binding Offer from KKR, by way of a Scheme, at A$88.00/share, in cash, a 36.7% premium to last close.</li>
<li>Presumably, Paul Ramsay's Ramsay Foundation, Ramsay's largest shareholder, is supportive, otherwise there is no deal.</li>
<li>Due diligence has been granted. If successful, this would be one of the largest LBOs by a private equity outfit in Australia. </li>
</ul>


Hospital operator Ramsay Health Care (RHC AU) has announced an unsolicited, non-binding Offer from KKR, by way of a Scheme, at A$88.00/share, in cash, a 36.7% premium to last close.
Presumably, Paul Ramsay's Ramsay Foundation, Ramsay's largest shareholder, is supportive, otherwise there is no deal.
Due diligence has been granted. If successful, this would be one of the largest LBOs by a private equity outfit in Australia. 


<ul>
<li>
<a href="https://www.smartkarma.com/entities/virtus-health-ltd" target="_blank" data-smartkarma-citation="entities:14776:1" rel="noopener">Virtus Health (VRT AU)</a> gives the nod to CapVest as the latter bumps to $8.25/share - less dividends - by way of a Scheme</li>
<li>CapVest will also make a concurrent off-market takeover Offer at $8.10, less dividends. This Offer can be triggered if the first Offer fails, and would only require 50.1% shareholder approval.</li>
<li>Trading one spread below CapVest's firm Scheme terms. Back in BGH's court. Again.</li>
</ul>



Virtus Health (VRT AU) gives the nod to CapVest as the latter bumps to $8.25/share - less dividends - by way of a Scheme
CapVest will also make a concurrent off-market takeover Offer at $8.10, less dividends. This Offer can be triggered if the first Offer fails, and would only require 50.1% shareholder approval.
Trading one spread below CapVest's firm Scheme terms. Back in BGH's court. Again.


Virtus Enters Into Firm Deal With CapVest

<ul>
<li>Fertility specialist <a href="https://www.smartkarma.com/entities/virtus-health-ltd" target="_blank" data-smartkarma-citation="entities:14776:1" rel="noopener">Virtus Health (VRT AU)</a> has received a revised non-binding <a href="https://www.smartkarma.com/compose/insight/66126/Vinva%20became%20a%20substantial%20shareholder%20on%20the%2022%20November." target="_blank" rel="noopener">takeover bid</a> from BGH Capital of $7.65/share, less any dividends declared by Virtus. It had previously offered $7.10/share.</li>
<li>BGH also said it would vote its 19.99% stake against CapVest Partners' cash offer of $7.60/share. </li>
<li>Back in CapVest's court. A $0.05/share higher bid is unlikely to see the UK-based player fold its tent.</li>
</ul>


Fertility specialist Virtus Health (VRT AU) has received a revised non-binding takeover bid from BGH Capital of $7.65/share, less any dividends declared by Virtus. It had previously offered $7.10/share.
BGH also said it would vote its 19.99% stake against CapVest Partners' cash offer of $7.60/share. 
Back in CapVest's court. A $0.05/share higher bid is unlikely to see the UK-based player fold its tent.


<ul>
<li>
<a href="https://www.smartkarma.com/entities/z-energy-ltd" target="_blank" data-smartkarma-citation="entities:9838:1" rel="noopener">Z Energy Ltd (ZEL NZ)</a>'s Scheme Booklet is now <a href="https://docs.publicnow.com/viewDoc?hash_primary=768E2B9BEC76822577987F21DC8BDD2F20F0A488" target="_blank" rel="noopener">out</a>. The Scheme Meeting will be held on the 25 March.</li>
<li>The Independent Advisor has concluded the Offer from <a href="https://www.smartkarma.com/entities/ampol-ltd" target="_blank" data-smartkarma-citation="entities:345:1" rel="noopener">Ampol (ALD AU)</a>  is fair and reasonable and in the best interest of ZEL shareholders.</li>
<li>The spread to terms is attractive here assuming implementation in the second quarter of 2022.  </li>
</ul>



Z Energy Ltd (ZEL NZ)'s Scheme Booklet is now out. The Scheme Meeting will be held on the 25 March.
The Independent Advisor has concluded the Offer from Ampol (ALD AU)  is fair and reasonable and in the best interest of ZEL shareholders.
The spread to terms is attractive here assuming implementation in the second quarter of 2022.  


Z Energy (ZEL NZ): Scheme Booklet Out. Meeting On The 25 March

New Zealand

Metlifecare Limited provides private health care services through its ownership, operation and management of retirement villages, nursing homes and geriatric hospitals along with the marketing of services allied to these facilities throughout New Zealand.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Metlifecare Ltd (MET NZ)

Arvida Group (ARV NZ): Stonepeak’s Binding Proposal at NZ$1.70

The offer is attractive, and shareholders representing 18% of outstanding shares are supportive. At the last close and for a November payment, the...

Arun George

Virtus Enters Into Firm Deal With CapVest

Trading one spread below CapVest's firm Scheme terms. It's possible BGH reloads. Or folds. Entering around here appears attractive. Plus there is a...

David Blennerhassett

BGH Ups The Ante For Control Of Virtus

Trading at a reasonably attractive gross spread of ~2.4% to the latest proposal. BGH's Offer adds just A$4mn to the consideration payout versus...

David Blennerhassett

Z Energy (ZEL NZ): Scheme Booklet Out. Meeting On The 25 March

Currently trading at a gross/annualised return of 3.9%/16.1%%, assuming early late May completion. Or 4.4%/13.4% with late June implementation. ...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Arvida Group (ARV NZ): Stonepeak’s Binding Proposal at NZ$1.70

The offer is attractive, and shareholders representing 18% of outstanding shares are supportive. At the last close and for a November payment, the...

Arun George

KKR Bids $88/Share For Ramsay Health

The Offer is indicative - for now. Trading at gross/annualised spread of 6.7%/12.6%, assuming early November completion. Not bad. Even better if...

David Blennerhassett

Virtus Enters Into Firm Deal With CapVest

Trading one spread below CapVest's firm Scheme terms. It's possible BGH reloads. Or folds. Entering around here appears attractive. Plus there is a...

David Blennerhassett

BGH Ups The Ante For Control Of Virtus

Trading at a reasonably attractive gross spread of ~2.4% to the latest proposal. BGH's Offer adds just A$4mn to the consideration payout versus...

David Blennerhassett

Z Energy (ZEL NZ): Scheme Booklet Out. Meeting On The 25 March

Currently trading at a gross/annualised return of 3.9%/16.1%%, assuming early late May completion. Or 4.4%/13.4% with late June implementation. ...

David Blennerhassett